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Globally there are an estimated 37.9 million people living with HIV 
(PLHIV), with ~20.6 million (54%) in the eastern and southern 
Africa region, and 7.7 million (20%) in South Africa (SA).[1] The 
current best estimate for antiretroviral (ART) coverage in SA is 62% 
of PLHIV, with only 54% having suppressed viral loads, translating 
into a significant number of individuals at high risk of opportunistic 
infections such as Pneumocystis jirovecii pneumonia (PCP).[2] 
Exponential spread of COVID-19 in SA is anticipated, and at the time 
of writing there were >2 000 confirmed cases in the country.[3] While 
there is currently no evidence to suggest that HIV infection confers 
an increased risk of either contracting COVID-19 or developing 
severe disease, it certainly does confound the diagnostic assessment 
and management of these patients.
Case report
A 41-year-old HIV-positive man self-presented to our designated 
COVID-19 test and treatment centre in Cape Town, SA. He complained 
of a 12-day history of fever, a non-productive cough, myalgia, diarrhoea, 
and gradually worsening dyspnoea. He was employed as a taxi driver, 
and had provided transport to international travellers for up to a day 
prior to symptom onset. He was unable to recall whether any of his 
passengers had flu-like symptoms. Three days prior to admission, 
he had presented to his local community health centre specifically 
requesting a test for COVID-19. However, since he did not meet the 
case definition at the time, he was treated symptomatically.
The patient’s medical history included ART since 2016 with a 
fixed-drug combination of tenofovir, emtricitabine and efavirenz. 
No recent CD4+ cell count was available, but the patient had an 
undetectable HIV viral load 6 months prior to this presentation, 
which was confirmed during his current admission. He had no 
history of tuberculosis (TB), AIDS-defining illnesses, or chronic 
cardiovascular or respiratory illnesses.
The initial clinical evaluation revealed that he was haemodynamically 
stable but had evidence of acute respiratory distress, including a 
peripheral oxygen saturation of 73% while breathing ambient air, and 
a respiratory rate of 28 breaths per minute. He was admitted directly 
to an isolation ward, where he was intubated under appropriate 
infection prevention and control measures and transferred to the 
intensive care unit.
Investigations
A chest radiograph (Fig. 1) demonstrated diffuse bilateral ground-
glass infiltrates, with patchy areas of consolidation. A full blood 
count revealed lymphopenia (white blood cell count 0.56 × 109/L, 
normal range 1.4 - 4.2 × 109/L) and a mildly reduced platelet count 
(166 × 109/L, normal range 171 - 388 × 109/L), with an absolute CD4+ 
cell count of 78 cells/µL. The C-reactive protein level was 225 mg/L 
(normal <10 mg/L), and the procalcitonin (PCT) level 0.97 µg/L 
(normal <0.1 µg/L). He had mild hepatic transaminitis and normal 
kidney function.
Differential diagnosis
The differential diagnosis included PCP, influenza or another viral 
pneumonia, TB and atypical bacterial pneumonia. Owing to the 
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The first critically ill patient admitted to our hospital in Cape Town, South Africa, during the COVID-19 pandemic was co-infected 
with HIV and SARS-CoV-2. Pneumocystis jirovecii pneumonia (PCP) and other respiratory opportunistic infections share many clinical 
features with severe COVID-19. Our understanding of the nuances of co-management of HIV and COVID-19 is evolving. We describe the 
diagnostic and therapeutic challenges presented by this case.
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clinical picture of a severe acute respiratory illness, COVID-19 
pneumonitis was included in the differential diagnosis.
Treatment
The patient was treated empirically with intravenous amoxicillin-
clavulanic acid for severe community-acquired bacterial pneumonia 
and azithromycin for atypical bacterial pneumonia, as well as 
trimethoprim-sulfamethoxazole for presumed PCP. Empirical 
oseltamivir was withheld, as his symptoms had been present for 
>72 hours.
Subsequent testing of endotracheal aspirates confirmed a positive 
polymerase chain reaction (PCR) for SARS-CoV-2, with a negative 
multiplex respiratory virus panel, negative Xpert MTB/RIF Ultra 
for TB, negative bacterial staining and culture, and negative 
immunofluorescence for P. jirovecii. Owing to the low sensitivity of 
the latter, a serum beta-D-glucan assay was requested, which revealed 
a level of <31 µg/mL.
Specific therapy included changing his ART to lamivudine, 
zidovudine and lopinavir/ritonavir for ease of administration in the 
intensive care unit (ICU) setting and adding chloroquine 650 mg 
daily for 2 days, and then 600 mg daily for 3 days.
Ethics approval
Ethics approval for this case study was granted by the Health 
Research Ethics Committee of Stellenbosch University (ref. no. 
N20/04/005_COVID-19).
Discussion
Our patient presented relatively late in the course of disease, 
and in retrospect the initial case definition should have included 
people who have close contact with international travellers. It 
is unclear whether the severity of our patient’s presentation can 
solely be attributed to the normal progression of COVID-19 in an 
immunocompromised patient or whether it was complicated by a 
bacterial infection (initial raised PCT which gradually dropped to 
0.46 µg/L on antibiotic treatment). In a resource-constrained setting, 
it is common practice to ration access to intensive care, particularly 
in patients with HIV infection who are not established on ART and 
whose case is complicated by AIDS-defining illnesses, owing to their 
historical poor prognosis.[4] At present we do not know what the 
outcomes of critically ill HIV/SARS-CoV-2 co-infected patients will 
be. When there is widespread community transmission of SARS-
CoV-2, with high numbers of severely ill patients requiring ICU care, 
distinguishing between COVID-19, PCP and other AIDS-defining 
illnesses at the outset will become of critical importance. In PLHIV 
and other immunocompromised populations, PCP remains an 
important differential diagnosis in patients with CD4+ cell counts 
<200 cells/µL who present with progressive lower respiratory tract 
symptoms, including a dry cough, shortness of breath, hypoxaemia 
and bilateral ground-glass infiltrates on radiological imaging. 
However, none of these features are specific for PCP, and they may 
also be consistent with COVID-19 pneumonitis. In our setting, the 
diagnosis of PCP in HIV-infected patients is made on clinical and 
characteristic chest radiographic features, without further extensive 
diagnostic testing. During the COVID-19 pandemic, we recommend 
further diagnostic testing when PCP is considered. This includes an 
expectorated sputum sample[5] (or a tracheal aspirate in the intubated 
patient) for PCR or immunofluorescence testing, and also a serum 
sample for beta-D-glucan. Owing to the potential for generating 
aerosols, obtaining an induced sputum sample for PCP testing is 
currently not advised.[6]
The World Health Organization clinical guideline[6] cautions 
against the routine use of corticosteroids in the management of 
COVID-19, outside the setting of a clinical trial. The rationale 
stems from evidence that corticosteroids conferred no survival 
benefit in other viral pneumonias such as severe acute respiratory 
syndrome (SARS), Middle Eastern respiratory syndrome (MERS) 
and influenza.[6] Conversely, withholding additional corticosteroids 
in HIV-infected patients with PCP and hypoxaemia is associated 
with worse outcomes.[7] On the available evidence at the time of 
submission, we do recommend initiating empirical corticosteroids 
in hypoxaemic patients with a high likelihood of PCP, and stopping 
them as soon as a COVID-19-positive result is confirmed and/or 
PCP test results are negative. These clinical dilemmas, along with 
other pertinent questions such as whether protease inhibitors offer 
some protection against SARS-CoV-2, or whether chloroquine, 
with potential ART drug interactions, has a role in the treatment 
of COVID-19 in PLHIV, should be explored in controlled clinical 
trials. [8] With increasing community transmission of SARS-CoV-2, 
our local case definition has evolved to include all patients presenting 
with a respiratory tract infection. In sub-Saharan Africa our resources 
are already constrained by the high burden of HIV-associated 
respiratory tract infections and TB. Adding the COVID-19 pandemic 
to the soup is potentially disastrous for our healthcare system and the 
community at large. The swift action by our government to contain 
the spread of the infection, and the dedication of the thousands of SA 
healthcare workers who are already experienced in the management 
of the complex clinical dilemmas presented by HIV, is reason for 
some hope in this crisis.
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Fig. 1. Chest radiograph.
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